AMENDMENTS TO THE CLAIMS

This listing replaces all prior listings of the claims.

Claims 1-4 (Cancelled)

5. (Currently amended) A pharmaceutical composition comprising a therapeutically effective delayed release oral dosage form of an interleukin-11 ("IL-11") polypeptide, wherein said composition comprises

an a polypeptide with the amino acid sequence of a human IL-11 polypeptide;

at least one binder;

at least one plasticizer;

at least one glidant; and

a methacrylic acid copolymer an enteric coat.

- 6. (Original) The pharmaceutical composition of claim 5, further comprising a carbohydrate.
- 7. (Original) The pharmaceutical composition of claim 6, wherein said carbohydrate comprises sucrose.
- 8. (Original) The pharmaceutical composition of claim 6, wherein said carbohydrate is present in said pharmaceutical composition at 60%-75% wt/wt.
- 9. (Currently Amended) he pharmaceutical composition of claim 9 claim 5, further comprising glycine.
- 10. (Original) The pharmaceutical composition of claim 9, wherein said glycine is present in said pharmaceutical composition at 1% to 4% wt/wt.

- 11. (Original) The pharmaceutical composition of claim 9, further comprising methionine.
- 12. (Original) The pharmaceutical composition of claim 11, wherein methionine is present in said composition at a concentration of 0.1% to 0.5% wt/wt.

13-16. (Cancelled)

- 17. (Original) The pharmaceutical composition of claim 9, wherein said IL-11 polypeptide is a recombinantly produced IL-11 polypeptide.
- 18. (Original) The pharmaceutical composition of claim 16, wherein said IL-11 polypeptide is a recombinantly produced IL-11 polypeptide.
- 19. (Original) The pharmaceutical composition of claim 5, wherein said at least one binder is hydroxypropyl methylcellulose (HPMC).
- 20. (Original) The pharmaceutical composition of claim 5, wherein HPMC is present in said composition at a concentration of 3%-7%.
- 21. (Original) The pharmaceutical composition of claim 5, wherein said at least one glidant is talc.
- 22. (Original) The pharmaceutical composition of claim 21, wherein talc is present in said composition at a concentration of 5% to 10%.
- 23. (Original) The pharmaceutical composition of claim 5, wherein said at least one plasticizer is triethyl citrate or polysorbate-80.

- 24. (Original) The pharmaceutical composition of claim 23, wherein said triethyl citrate is present in said composition at a concentration of 1%-2% wt/wt.
- 25. (Original) The pharmaceutical composition of claim 23, wherein said polysorbate-80 is present in said composition at a concentration of 0.015% -0.045% wt/wt.
- 26. (Original) The pharmaceutical composition of claim 5, wherein said at least one plasticizer is triethyl citrate.

27. (Cancelled)

- 28. (Currently amended) A pharmaceutical composition comprising a therapeutically effective delayed release oral dosage form of an a polypeptide comprising the amino acid sequence of a human Interleukin-11 ("IL-11") polypeptide, wherein said IL-11 polypeptide is substantially enveloped by a first sealing coat, an enteric coating layer, and a second sealing coat, wherein said enteric coating layer is substantially disposed between said first and second sealing coat.
- 29. (Original) The pharmaceutical composition of claim 28, wherein at least one of said first sealing coat and said second sealing coat is HPMC.
- 30. (Original) The pharmaceutical composition of claim 28, wherein said first sealing coat and said second sealing coat comprise HPMC.
- 31. (Original) The pharmaceutical composition of claim 28, wherein said enteric coating layer comprises a methacrylic acid copolymer.
- 32. (Original) The pharmaceutical composition of claim 28, wherein said IL-11 polypeptide is provided disposed on a carbohydrate.

- 33. (Original) The pharmaceutical composition of claim 32, wherein said carbohydrate is sucrose.
- 34. (Original) The pharmaceutical composition of claim 28, further comprising methionine.
 - 35. (Original) The pharmaceutical composition of claim 28, further comprising glycine.
 - 36. (Original) The pharmaceutical composition of claim 28, further comprising a glidant.
 - 37. (Original) The pharmaceutical composition of claim 36, wherein said glidant is talc.
- 38. (Original) The pharmaceutical composition of claim 28, wherein said composition is provided as a capsule or a tablet.
- 39. (Original) The pharmaceutical composition of claim 38, wherein said composition is provided as a tablet.
- 40. (Original) The pharmaceutical composition of claim 38, wherein said composition is provided as a capsule.
- 41. (Original) The pharmaceutical composition of claim 40, wherein said capsule is a gelatin capsule.
- 42. (Withdrawn) A method of delivering a bioactive polypeptide to a subject, the method comprising orally administering to said subject the pharmaceutical composition of claim 1 in an amount sufficient to elicit a biological response in said subject.

- 43. (Withdrawn) A method of delivering an interleukin-11 ("IL-11") polypeptide to a subject, the method comprising orally administering to said subject the pharmaceutical composition of claim 5 in an amount sufficient to elicit a biological response in said subject.
- 44. (Withdrawn) The method of claim 43, wherein said IL-11 polypeptide elicits a biological response in the small intestine of said subject.
 - 45. (Withdrawn) The method of claim 43, wherein said subject is a human.
- 46. (Withdrawn) The method of claim 43, wherein said IL-11 polypeptide is administered in a composition comprising
 - at least one binder;
 - at least one plasticizer;
 - at least one glidant; and
 - a methacrylic acid copolymer.
- 47. (Withdrawn) The method of claim 43, wherein said interleukin-11 (IL-11) polypeptide is recombinant human IL-11.
- 48. (Withdrawn) A method of treating inflammatory bowel disease in a subject, the method comprising orally administering to a subject in need thereof a therapeutically effective dose of IL-11.
- 49. (Withdrawn) The method of claim 48, wherein said inflammatory disease is ulcerative colitis.
- 50. (Withdrawn) The method of claim 48, wherein said inflammatory disease is Crohn's disease.
 - 51. (Withdrawn) The method of claim 48, wherein said subject is a human.

52. (Withdrawn) The method of claim 48, wherein said IL-11 polypeptide is administered in a composition comprising

at least one binder;

at least one plasticizer;

at least one glidant; and

a methacrylic acid copolymer.

- 53. (New) The pharmaceutical composition of claim 5, wherein said enteric coat is ethylcellulose.
- 54. (New) The pharmaceutical composition of claim 5, wherein said enteric coat is hydroxypropyl methylcellulose.
- 55. (New) The pharmaceutical composition of claim 5, wherein said enteric coat is a methacrylic acid copolymer.